E. B. Walker, D. Haley, W. Miller, K. Floyd, K. P. Wisner, N. Sanjuan, H. Maecker, P. Romero, H.-M. Hu, W. G. Alvord, J. W. Smith II, B. A. Fox and W. J. Urba, “Gp100209-2M Peptide Immunization of Human Lymphocyte Antigen-A2+ Stage 1-III Melanoma Patients Induces Significant Increase in Antigen-Specific Effector and Long-Term Memory CD8+ T Cells,” Clinical Cancer Research, Vol. 10, No. 2, 2004, pp. 668-680. doi:10.1158/1078-0432.CCR-0095-03

has been cited by the following article:

• TITLE: Melanoma Immunotherapy: Overcoming Obstacles to Augment Anti-Tumor Immune Responses

  AUTHORS: Kristian M. Hargadon

  KEYWORDS: Melanoma; Tumor Immunotherapy; Dendritic Cell; Tumor Antigen; T Cell; Vaccine; Adoptive Transfer

  JOURNAL NAME: Journal of Cosmetics, Dermatological Sciences and Applications, Vol.3 No.2A, June 20, 2013

  ABSTRACT: Melanoma is the most aggressive form of skin cancer and accounts for the vast majority of skin cancer-related deaths. Its ability to metastasize quickly, often before diagnosis, makes this cancer difficult to treat with traditional therapies. The identification of anti-melanoma immune responses in patients and the discovery of tumor antigens targeted by these immune responses have paved the way for immunotherapy as a novel approach to treating this cancer. In this review, the major immunotherapies targeting these melanoma tumor antigens are discussed. The advantages and limitations of peptide-, protein-, and gene-based vaccination maneuvers and adoptive cell transfer therapies are emphasized. Recent insights into melanoma immune evasion strategies are also highlighted, with particular focus on how our increasing knowledge of tumor/immune cell interactions is driving the development of novel immunotherapeutic strategies for the treatment of melanoma.